{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:35:08Z","timestamp":1773808508406,"version":"3.50.1"},"reference-count":75,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000380","name":"Guy's and St Thomas\u2019 Charity","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000380","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Marie Pedersen and Jensine Heiberg Foundation"},{"name":"The NIHR Collaboration for Leadership in Applied Health Research and Care South London"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The increase in opioid prescribing in many European countries over the last decade has raised concerns about associated diversion, overdose, and mortality. Fentanyl is one of these synthetic opioids that is typically prescribed as a transdermal patch for pain that requires continuous pain relief and has been the focus of investigation due to reports of overdose and death. We report a case series of 14 drug addiction treatment entrants, who entered treatment in a service located in the region of Southern Denmark from August 2015 to December 2015 for smoking fentanyl patches. Clients presented with difficulties breathing and pains in the lungs. The clients had a history of past opioid use, including heroin. Relapses resulted in treatment disengagement. Immunoassays for fentanyl were used in the service. In some cases, false negative results occurred. Clients' urine samples were subsequently analysed in a collaborating laboratory. Seven clients tested positive for fentanyl. One client was positive for both fentanyl and heroin. Analyses were also positive for other opioids and metabolites in 6 clients, predominantly codeine and oxycodone. Results from confirmatory analysis contributed to clearer insights into clients' drug histories, which facilitated personalised care plans consisting of opioid agonist therapy informed by confirmed drug use. In Denmark, prescription levels of fentanyl are high, which has been accompanied by observations of diversion and smoking in a smaller population. In addition to revision of inappropriate prescribing to reduce diversion, we recommend increased reliance upon confirmatory drug analysis in the addiction treatment sector in Denmark.<\/jats:p>","DOI":"10.1002\/dta.2397","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T21:54:59Z","timestamp":1524174899000},"page":"917-926","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characteristics of opioid\u2010maintained clients smoking fentanyl patches: The importance of confirmatory drug analysis illustrated by a case series and mini\u2010review"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2080-9865","authenticated-orcid":false,"given":"Andreas","family":"Kimerg\u00e5rd","sequence":"first","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-5858","authenticated-orcid":false,"given":"Jacklyn","family":"Dunne","sequence":"additional","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"B\u00f8gen","sequence":"additional","affiliation":[{"name":"Drug Rehabilitation Centre  Fredericia Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hindersson","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry North Denmark Regional Hospital (Aalborg University)  Hj\u00f8rring Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-1983","authenticated-orcid":false,"given":"Torben","family":"Breindahl","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry North Denmark Regional Hospital (Aalborg University)  Hj\u00f8rring Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1615145"},{"issue":"10","key":"e_1_2_8_3_1","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2010\u20132014","volume":"65","author":"Warner M","year":"2016","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_2_8_4_1","unstructured":"EMCDDA.Fentanyl in Europe. EMCDDA trendspotter study. Lisbon: EMCDDA;2012.http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_191974_EN_TD3112230ENN_Fentanyl.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13528"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-017-0367-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2046"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkx050"},{"key":"e_1_2_8_9_1","unstructured":"EMCDDA.Risk assessment report on a new psychoactive substance: N\u2010(4\u2010Fluorophenyl)\u2010N\u2010(1\u2010 phenethylpiperidin\u20104\u2010yl)isobutyramide (4\u2010fluoroisobutyrylfentanyl; 4F\u2010iBF). Lisbon: EMCDDA;2017.http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_259558_EN_4F\u2010iBF_RAR_with%20Annexes%20and%20cover.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_10_1","unstructured":"EMCDDA.Acryloylfentanyl. Report on the risk assessment of N\u2010(1\u2010phenethylpiperidin\u20104\u2010yl)\u2010N\u2010 phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances. Lisbon: EMCDDA;2017.http:\/\/www.emcdda.europa.eu\/publications\/risk\u2010assessments\/acryloylfentanyl_en. Accessed March 21 2018."},{"key":"e_1_2_8_11_1","unstructured":"EMCDDA.Furanylfentanyl. Report on the risk assessment of N\u2010phenyl\u2010 N\u2010[1\u2010(2\u2010phenylethyl)piperidin\u20104\u2010yl] furan\u20102\u2010carboxamide (furanylfentanyl) in the framework of the Council Decision on new psychoactive substances. Lisbon: EMCDDA;2017.http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/6712\/20176480_TDAK17002ENN_PDF.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_12_1","unstructured":"EMCDDA. Risk assessment report on a new psychoactive substance: Methyl 1\u2010(2\u2010phenylethyl)\u20104\u2010 [phenyl(propanoyl)amino]piperidine\u20104\u2010carboxylate (carfentanil). Lisbon: EMCDDA;2017.http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_259560_EN_Carfentanil_RAR_with%20Annexes%20and%20cover.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.04.061"},{"key":"e_1_2_8_14_1","unstructured":"World Health Organization.WHO model list of essential medicines.http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1. Accessed December 12 2017."},{"issue":"8","key":"e_1_2_8_15_1","first-page":"V07130459","article-title":"Fentanylte [Fentanyl tea]","volume":"176","author":"Darling SS","year":"2014","journal-title":"Fentanylte Ugeskr Laeger"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.09.014"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.11.027"},{"issue":"1","key":"e_1_2_8_18_1","first-page":"26","article-title":"Hatte sich das pflaster in rauch aufgel\u00f6st? \u2010 Eine t\u00f6dliche fentanylintoxikation [Has the transdermal patch gone up in smoke? A fatal fentanyl intoxication]","volume":"224","author":"Oechsler S","year":"2009","journal-title":"Arch Kriminol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2016.1246571"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.01.2009.1454"},{"key":"e_1_2_8_21_1","unstructured":"Fredericia Kommune.Alkohol\u2010 og Stofbehandlingen [Alcohol and drug treatment].https:\/\/www.fredericia.dk\/borger\/omsorg\u2010sundhed\/krop\u2010sind\/alkohol\u2010stofbehandlingen. Accessed April 8 2018."},{"key":"e_1_2_8_22_1","unstructured":"Socialtilsyn Syd.Tilsynsrapport [Service evaluation report]. Ringe: Socialtilsyn Syd;2017."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00276-5"},{"key":"e_1_2_8_24_1","unstructured":"EMCDDA.Denmark: Country drug report 2017. Lisbon: EMCDDA;2017.http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/4515\/TD0416913ENN.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw067"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/28.6.422"},{"issue":"3","key":"e_1_2_8_27_1","first-page":"1","article-title":"Acute inhalation toxicity of smoke of fentanyl and its 1\u2010substituted analogs in Swiss albino mice","volume":"60","author":"Yadav SK","year":"2014","journal-title":"Cell Mol Biol"},{"key":"e_1_2_8_28_1","first-page":"201","article-title":"Inhalation studies with drugs of abuse","volume":"173","author":"Meng Y","year":"1997","journal-title":"NIDA Res Monogr"},{"issue":"1","key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3565(25)20938-7","article-title":"Inhalation exposure to volatilized opioids produces antinociception in mice","volume":"279","author":"Lichtman AH","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4628(20000829)77:9<1894::AID-APP5>3.0.CO;2-Y"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/00268970802077876"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1794"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1462"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00724.x"},{"key":"e_1_2_8_35_1","unstructured":"AndreasenJ.Forbruget af smerteplaster stiger kraftigt [Use of pain patches increases significantly]. Ugeskr Laeger.2005.http:\/\/ugeskriftet.dk\/nyhed\/forbruget\u2010af\u2010smerteplaster\u2010stiger\u2010kraftigt. Accessed July 11 2017."},{"issue":"20","key":"e_1_2_8_36_1","first-page":"1975","article-title":"The use of analgesics in Denmark, 2000\u20102004","volume":"168","author":"Rosenzweig M","year":"2006","journal-title":"Ugeskr Laeger"},{"issue":"46","key":"e_1_2_8_37_1","first-page":"3173","article-title":"Det legale opioidforbrug i Danmark [The licit opioid consumption in Denmark]","volume":"172","author":"Jarlbaek L","year":"2010","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_8_38_1","unstructured":"Danish Health Authority.Kortl\u00e6gning af opioidforbruget i Danmark [Overview of the use of opioids in Denmark].https:\/\/www.sst.dk\/da\/Feeds\/~\/media\/69913B827BAA4850A9A70E0CF76CB305.ashx. Accessed December 27 2017."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2015.01.003"},{"key":"e_1_2_8_40_1","unstructured":"Danish Health Authority.Narkotikasituationen i Danmark[The annual drug report for Denmark 2016]. Copenhagen: Danish Health Authority;2016."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_8_42_1","unstructured":"Danish Medicines Agency.Interaktive bivirkningsoversigter[Interactive adverse drug reaction reports]https:\/\/laegemiddelstyrelsen.dk\/da\/bivirkninger\/bivirkninger\u2010ved\u2010medicin\/interaktive\u2010bivirkningsoversigter\/Drug%20Details\/?drug=.\/DK_EXTERNAL\/NONCOMBINED\/DK_NON_000332172121.zip&agency=DKMA&lang=Danish. Accessed June 3 2017."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5108"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078390315612262"},{"key":"e_1_2_8_45_1","unstructured":"LarsenHL JohansenHL GlintborgD.Irrationelt brug af st\u00e6rke opioider[Irrational use of potent opioids].RationelFarmakoterapi.2011;3.https:\/\/www.sst.dk\/da\/rationel\u2010farmakoterapi\/maanedsbladet\/2011\/maanedsblad_nr_3_marts_2011\/irrationelt_brug_af_staerke_opioider. Accessed June 3 2017."},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170628"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001060"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1715163517743993"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502901001"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/NHH.0000000000000563"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S116091"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00283.x"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000337028"},{"key":"e_1_2_8_54_1","unstructured":"EMCDDA.Strategies to prevent diversion of opioid substitution treatment medications. Lisbon: EMCDDA;2016.http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2936\/OST%20medications_POD2016.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.150329"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2008.02.016"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659409000433"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1415-y"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1081\/ADA-100104509"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.09.81"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku075"},{"issue":"2","key":"e_1_2_8_62_1","first-page":"SE1","article-title":"Immunoassay\u2010Based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain","volume":"20","author":"Snyder ML","year":"2017","journal-title":"Pain Physician"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku103"},{"issue":"1","key":"e_1_2_8_64_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/clinchem\/48.1.205","article-title":"False\u2010positive lysergic acid diethylamide immunoassay screen associated with fentanyl medication","volume":"48","author":"Gagajewski A","year":"2002","journal-title":"Clin Chem"},{"key":"e_1_2_8_65_1","unstructured":"Health Canada.Information Update \u2013 Health Canada is advising Canadians of the potential limitations when using test strips to detect fentanyl \u2013 Recalls and safety alerts.healthycanadians.gc.ca\/recall\u2010alert\u2010rappel\u2010avis\/search\u2010recherche\/simple\/en\/. Accessed December 27 2017."},{"key":"e_1_2_8_66_1","first-page":"180","article-title":"Nye psykoaktive stoffer kr\u00e6ver et paradigmeskifte i misbrugstestning i Danmark [New psychoactive substances require a paradigm shift in drug testing in Denmark]","author":"Breindahl T","year":"2018","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_8_67_1","unstructured":"Danish Health Authority.Vejledning til l\u00e6ger der behandler opioidafh\u00e6ngige patienter med substitutionsmedicin[Guidelines for physicians treating opioid dependent patients with substitution opioids]. Copenhagen: Danish Health Authority;2017."},{"key":"e_1_2_8_68_1","unstructured":"BreindahlT HinderssonP HardleiT BrockB EriksenK HannibalJ.Retningslinjer for udf\u00f8relse af misbrugsanalyser i klinisk biokemi[Guidelines for drugs\u2010of\u2010abuse testing in clinical biochemistry].http:\/\/www.dskb.dk\/Clubs\/CommonDrive\/Components\/GetWWWFile.aspx?fileID=40899. Accessed December 27 2017."},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/33.8.418"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13436"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2018.01.021"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2016.04.046"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-016-0862-1"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1764-1"},{"key":"e_1_2_8_75_1","unstructured":"EMCDDA.European Drug Report. Trends and Developments 2016. Lisbon: EMCDDA;2016.http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2637\/TDAT16001ENN.pdf. Accessed March 21 2018."},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2016.10.006"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:22:58Z","timestamp":1760383378000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/dta.2397"],"URL":"https:\/\/doi.org\/10.1002\/dta.2397","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"2017-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}